C4 Therapeutics Files DEF 14A on Executive Compensation
Ticker: CCCC · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
C4 Therapeutics DEF 14A out: Executive pay details for 2024, including equity awards for PEOs and others.
AI Summary
C4 Therapeutics, Inc. filed a DEF 14A with the SEC on April 29, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to both principal executive officers (PEO) and non-PEO/non-NEO members for the fiscal years 2022, 2023, and 2024, along with year-end values of outstanding and unvested equity awards.
Why It Matters
This filing provides transparency into how C4 Therapeutics compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that primarily discloses executive compensation and corporate governance information, not typically indicative of immediate financial risk.
Key Numbers
- 2024 — Fiscal Year End (The filing covers executive compensation for the fiscal year ending December 31, 2024.)
- 2023 — Fiscal Year End (The filing includes data on equity awards for the fiscal year ending December 31, 2023.)
- 2022 — Fiscal Year End (The filing provides information on equity awards for the fiscal year ending December 31, 2022.)
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Filer of the DEF 14A
- 490 Arsenal Way, Suite 120, Watertown, MA 02472 (address) — Business and mailing address of C4 Therapeutics, Inc.
- 0001662579 (company_id) — Central Index Key for C4 Therapeutics, Inc.
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed with the SEC to solicit shareholder votes on important corporate matters, typically including the election of directors and executive compensation.
When was this DEF 14A filing submitted by C4 Therapeutics, Inc.?
C4 Therapeutics, Inc. filed this DEF 14A on April 29, 2025.
What specific types of compensation data are detailed in this filing for C4 Therapeutics, Inc.?
The filing details equity awards granted to Principal Executive Officers (PEO) and Non-PEO/Non-NEO members, as well as the year-end values of outstanding and unvested equity awards for the fiscal years 2022, 2023, and 2024.
What is C4 Therapeutics, Inc.'s fiscal year end?
C4 Therapeutics, Inc.'s fiscal year ends on December 31st.
What is the SIC code for C4 Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for C4 Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding C4 Therapeutics, Inc. (CCCC).